CGT indicates complicated grief treatment; CIT, citalopram; PLA, placebo.
A, Scores on the Inventory of Complicated Grief (ICG) show improvement in participants randomized to complicated grief treatment (CGT) but no specific benefit of citalopram (CIT) relative to placebo (PLA). B, Depression self-ratings on the Quick Inventory of Depressive Symptoms (QIDS) show improvement when CIT is co-administered with CGT but little improvement in the absence of CGT. The ICG total score range is 0 to 76; the QIDS total score range is 0 to 27. IPW indicates inverse probability weighting.
eAppendix 1. Details of the main statistical analyses.
eAppendix 2. Results of the moderator analyses on the primary outcome.
eAppendix 3. Results of the longitudinal analyses on the primary and secondary outcomes.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Shear MK, Reynolds CF, Simon NM, et al. Optimizing Treatment of Complicated GriefA Randomized Clinical Trial. JAMA Psychiatry. 2016;73(7):685–694. doi:10.1001/jamapsychiatry.2016.0892
Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To our knowledge, this is the first placebo-controlled randomized clinical trial to evaluate the efficacy of antidepressant pharmacotherapy, with and without complicated grief psychotherapy, in the treatment of complicated grief.
To confirm the efficacy of a targeted complicated grief treatment (CGT), determine whether citalopram (CIT) enhances CGT outcome, and examine CIT efficacy without CGT.
Design, Setting, and Participants
Included in the study were 395 bereaved adults who met criteria for CG recruited from March 2010 to September 2014 from academic medical centers in Boston, Massachusetts; New York, New York; Pittsburgh, Pennsylvania; and San Diego, California. Co-occurring substance abuse, psychosis, mania, and cognitive impairment were exclusionary. Study participants were randomized using site-specific permuted blocks stratified by major depression into groups prescribed CIT (n = 101), placebo (PLA; n = 99), CGT with CIT (n = 99), and CGT with PLA (n = 96). Independent evaluators conducted monthly assessments for 20 weeks. Response rates were compared under the intention-to-treat principle, including all randomized participants in a logistic regression with inverse probability weighting.
All participants received protocolized pharmacotherapy optimized by flexible dosing, psychoeducation, grief monitoring, and encouragement to engage in activities. Half were also randomized to receive manualized CGT in 16 concurrent weekly sessions.
Main Outcomes and Measures
Complicated grief–anchored Clinical Global Impression scale measurments every 4 weeks. Response was measured as a rating of “much improved” or “very much improved.”
Of the 395 study participants, 308 (78.0%) were female and 325 (82.3%) were white. Participants’ response to CGT with PLA vs PLA (82.5% vs 54.8%; relative risk [RR], 1.51; 95% CI, 1.16-1.95; P = .002; number needed to treat [NNT], 3.6) suggested the efficacy of CGT, and the addition of CIT did not significantly improve CGT outcome (CGT with CIT vs CGT with PLA: 83.7% vs 82.5%; RR, 1.01; 95% CI, 0.88-1.17; P = .84; NNT, 84). However, depressive symptoms decreased significantly more when CIT was added to treatment (CGT with CIT vs CGT with PLA: model-based adjusted mean [standard error] difference, −2.06 [1.00]; 95% CI, −4.02 to −0.11; P = .04). By contrast, adding CGT improved CIT outcome (CIT vs CGT with CIT: 69.3% vs 83.7%; RR, 1.21; 95% CI, 1.00-1.46; P = .05; NNT, 6.9). Last, participant response to CIT was not significantly different from PLA at week 12 (45.9% vs 37.9%; RR, 1.21; 95% CI, 0.82-1.81; P = .35; NNT, 12.4) or at week 20 (69.3% vs 54.8%; RR, 1.26; 95% CI, 0.95-1.68; P = .11; NNT, 6.9). Rates of suicidal ideation diminished to a substantially greater extent among participants receiving CGT than among those who did not.
Conclusions and Relevance
Complicated grief treatment is the treatment of choice for CG, and the addition of CIT optimizes the treatment of co-occurring depressive symptoms.
clinicaltrials.gov Identifier: NCT01179568
Complicated grief (CG) is a chronic impairing condition that occurs in about 7% of bereaved people (2% to 3% of general population).1,2 The syndrome includes persistent maladaptive thoughts, dysfunctional behaviors, and poorly regulated emotionality that interfere with adaptation after loss.3 Although co-occurring depressive symptoms are common, CG can be clearly differentiated from major depression both in its primary symptomatology4 and response to treatment.5,6 Core symptoms of yearning and sorrow, preoccupying thoughts of the deceased, and difficulty accepting the painful reality of the death are different from persistent depressed mood, anhedonia, worthlessness, and psychomotor and neurovegetative symptoms, which are the hallmarks of depression. Studies5,6 document a significantly better response to complicated grief treatment (CGT) than interpersonal psychotherapy, which has well-documented efficacy for depression.3
Provisional guidelines and criteria for diagnosis have been proposed for the International Statistical Classification of Diseases, Eleventh Revision3 and DSM-5.7 Until these are approved, patients can be reliably identified by a screening questionnaire8 and a semistructured clinical interview.9 Chronic high levels of distress and impairment and increased risk for suicide, cancer, and cardiovascular disease constitute a strong indication for treatment. We developed CGT to target adaptation to loss and found it produced a better outcome than grief-focused interpersonal psychotherapy5,6; individuals in our psychotherapy trial who were taking antidepressant medication had a markedly higher treatment completion rate. In addition, antidepressant medications can decrease the intensity of emotions and somatic symptoms and improve cognitive functioning, and there are some pilot data suggesting that antidepressant medication can be helpful for people with CG.10-12 However, to our knowledge, there are no randomized clinical studies testing whether antidepressants enhance CGT efficacy or whether they are efficacious without CGT.13 We conducted a randomized clinical trial to test the hypothesis that citalopram (CIT) would be superior to pill placebo (PLA) with and without CGT. Our data provide important information for evidence-informed clinical care and shared decision-making in specialty mental health and other health care settings.
Question Does citalopram (CIT) enhance complicated grief treatment (CGT) outcome, and is CIT efficacious without CGT?
Findings In this 4-site randomized clinical trial of 395 adults, there was a significantly greater rate of responders (ie, complicated grief much improved or very much improved) to CGT with placebo vs placebo. The addition of CIT did not improve the complicated grief response rate. However, depressive symptoms on the Quick Inventory of Depression Scale decreased significantly when CIT was added.
Meaning Complicated grief treatment is the treatment of choice for complicated grief, and the addition of CIT optimizes treatment of co-occurring depressive symptoms.
We conducted a double-blinded, PLA-controlled trial at 4 collaborating sites (New York, New York, which was the coordinating center; Boston, Massachusetts; Pittsburgh, Pennsylvania; and San Diego, California) funded independently by the National Institute of Mental Health. Aim 1 compared CIT with PLA when administered without CGT for 12 weeks (we moved aim 1 from week 16 to week 12 in consultation with our data and safety monitoring board after a US Food and Drug Administration ruling limited the maximum dose of CIT to 40 mg daily in 2011). Aim 2 compared CIT with PLA when administered with CGT. Aim 3 examined whether adding CGT to CIT or PLA significantly improved outcomes at 20 weeks. The institutional review boards at each site approved the study; oversight was provided by an independent data and safety monitoring board. The full study protocol can be found in Supplement 1. Written informed consent was obtained from all participants before baseline assessment. Following a telephone screen (verbal consent) and in-person assessment, eligible participants were randomly assigned via a 2 × 2 factorial design to receive CIT or PLA with or without concomitant psychotherapy. All study participants received a medication prescription (CIT or PLA) from a pharmacotherapist who provided empathic support, psychoeducation, and encouragement to re-engage in activities along with monitoring and adjustment of the medication. Half also received CGT, a targeted psychotherapy entailing 16 sessions over a maximum of 20 weeks.5,6 Our main outcome was rate of response defined as 1 (“very much improved”) or 2 (“much improved”) on the CG-anchored Clinical Global Impression Scale14 (Table 1) as determined by independent evaluators, trained to achieve reliability on key rating instruments (treatment response κ, 0.89; 95% CI, 0.73-1.00) and blind to treatment assignment.
Between March 2010 and September 2014, 395 bereaved individuals aged 18 to 95 years were recruited using professional and public outreach and print, broadcast, and internet media. Referrals were made by health care professionals, bereavement counselors, and patients or family members.
Participants who scored 30 or greater on the Inventory of Complicated Grief (ICG)8 underwent a clinical interview to confirm the presence and primacy of CG. Those with a current substance use disorder (past 6 months), a lifetime history of psychotic disorder, bipolar I disorder, active suicidal plans requiring hospitalization, a Montreal Cognitive Assessment score less than 21, or a pending lawsuit or disability claim related to the death as well as those undergoing concurrent psychotherapy or treatment with an antidepressant were excluded.
Independent evaluators completed the Structured Clinical Interview for DSM-IV Axis I,15 a supplemental interview for CG,9 the Columbia Suicide Scale16 modified for bereavement, and the Clinical Global Impression Scale14 for CG-anchored severity and improvement (Table 1). Follow-up assessments were conducted 4, 8, 12, 16, and 20 weeks after the first treatment visit and 6 months after study treatment termination. Study participants were instructed not to tell independent evaluators if they received CGT. Assessments were audiotaped; 10% were randomly selected and corated for reliability. Biweekly cross-site meetings reviewed rating procedures and included practice coratings to prevent drift.
Participants completed self-report questionnaires for secondary outcome measures of grief-related symptoms (ICG),8 impairment (Work and Social Adjustment Scale [WSAS]),17,18 avoidance (Grief-Related Avoidance Questionnaire [GRAQ]),19 depressive symptoms (Quick Inventory of Depressive Symptoms–Self-report [QIDS-SR16]),20 and suicidal ideation (Columbia Suicide Scale).16
Citalopram or PLA was provided in double-blind fashion to all participants. Given participants’ high levels of distress and impairment and inclusion of a PLA-only cell, our manualized pharmacotherapy approach included procedures designed to optimize participant safety and pharmacotherapy effectiveness. Prescribing clinicians received standardized site-based training and supervision. The first visit (about 45 minutes) included a focused psychosocial history and review of symptoms as well as psychoeducation using the same model as in CGT, with a rationale for using antidepressant medication. Subsequent visits (weekly for 4 weeks, biweekly for 4 weeks, and monthly thereafter) were 20 to 30 minutes. Pharmacotherapists monitored grief symptoms and provided CGT-informed clinical management that included encouragement and support for resuming normal life activities as a test of medication effectiveness. They also assessed depressive symptoms, suicidal thinking, medication adherence, and adverse effects. Specific interventions, such as exposure instructions, emotion regulation strategies, or cognitive reframing, were proscribed (specific exposure procedures and other CG-targeted psychotherapy procedures were prohibited). Medication was flexibly dosed to the maximum allowable. Supplementary visits were provided if there was a change in dosage or when it was deemed clinically indicated (eg, to follow-up on suicidal ideation). Study medication was discontinued and open treatment provided when exit criteria were met or when pharmacotherapists judged it was clinically indicated. Participants also interacted with warm, supportive, CGT-informed administrative staff. The mean (SD) dose of CIT (aim 1, week 12) was 33.9 (15.0) mg per day. The median dose was 40 mg per day.
Complicated grief treatment was delivered as in prior studies5,6 using a manualized, well-specified 16-session protocol. Briefly, sessions 1 through 3 included history taking (relationship history and bereavement experience), the beginning of daily grief-monitoring, psychoeducation about CG and CGT, the introduction of ongoing aspirational goals work, and a conjoint session with a significant other. Sessions 4 through 9 included imaginal and situational revisiting procedures and work with memories and pictures. Session 10 was a midcourse review, followed by sessions 11 through 16, which included an imaginal conversation with the deceased. The entire study treatment manual is available at http://www.complicatedgrief.columbia.edu/. Therapists were trained by participating in a didactic seminar and successfully completed at least 2 training cases before seeing study participants under independent site-based supervision.
Study participants were randomized with equal probability (25%) to each treatment arm, using permuted-block randomization (block size of 4 or 8) stratified by site and by presence or absence of current major depressive disorder (MDD). Medication allocation was concealed from all study staff. Independent evaluators were blind to psychotherapy allocation.
The range and distribution of all key demographic and clinical variables at baseline were compared across study arms by χ2 tests or analyses of variance. Our prespecified primary analysis was cross-sectional, comparing treatment response rates for CIT vs PLA at week 12 (aim 1), for CIT with CGT vs PLA with CGT at week 20 (aim 2), and for CIT with CGT vs CIT at week 20 (aim 3) based on the intention-to-treat principle including all randomized participants. A weighted logistic regression controlled for randomization stratification variables (ie, site and baseline MDD) and race/ethnicity. Inverse probability weighting, a standard strategy to account for missing assessment data,21-24 provided weights in the model (eAppendix 1 in Supplement 2). Our enrollment target of 440 participants lost 10% to follow-up and had a power of 76% to 83% to detect predicted between-group difference in response based on data from our 2005 study5,11 (CGT with PLA, 40%; CGT with CIT, 60%; CIT, 40%; and PLA, 20%). All P values were 2-tailed, and statistical significance was defined as P < .05. Data were analyzed using SAS version 9.3 (SAS Institute).25
As with prespecified sensitivity analyses, unweighted analyses of assessment completers and longitudinal analyses using generalized linear mixed effects model with participant-specific random intercepts of the primary outcome were performed for each aim. We calculated number needed to treat (NNT) as the reciprocal of response rate. Preplanned moderator analyses examined treatment by MDD interaction (eAppendix 2 in Supplement 2) and treatment effect heterogeneity across sites.
Prespecified secondary analyses of self-report ratings of CG symptoms (ICG),8 grief-related functional impairment (WSAS)17,18 and avoidance (GRAQ)19 and of depressive symptoms (QIDS-SR16)20 compared changes in scores using a weighted linear regression using inverse probability weighting to adjust for missing assessments. As with sensitivity analyses, longitudinal mixed effects models with participant-specific random intercepts used all available longitudinal assessments to estimate the adjusted mean difference in week 12 and week 20 self-report outcomes (eAppendix 3 in Supplement 2). Suicidal ideation, a binary outcome derived from Columbia Suicide Scale question 1c,16 was analyzed the same way as treatment response.
Figure 1, the study CONSORT flowchart, outlines screening, assessment, and study completion rates.
Baseline sample characteristics are summarized in Table 2. The sample was predominantly white (325 of 395 [82.3%]), female (308 [78.0%]), and highly educated (350 [88.6%]), with slightly more than half (211 [53.4%]) completing college. The median (range) time since the loss was 2.3 (0.5-58.7) years. Most deaths were from natural causes. Two-thirds (262 [66.3%]) of the sample met criteria for current major depression. More than half (221 [55.9%]) reported a wish to be dead since the loss.
Analyses suggested a greater response to CGT with PLA than PLA (82.5% vs 54.8%; relative risk [RR], 1.51; 95% CI, 1.16-1.95; P = .002; NNT, 3.6). Contrary to our expectation, we could not show that the addition of CIT significantly improved CGT outcome (CGT with CIT vs CGT with PLA: 83.7% vs 82.5%; RR, 1.01; 95% CI, 0.88-1.17; P = .84; NNT, 84). On the other hand, adding CGT did improve CIT outcome (CIT vs CGT with CIT: 69.3% vs 83.7%; RR, 1.21; 95% CI, 1.00-1.46; P = .05; NNT, 6.9). Response to CIT was not statistically different from PLA (45.9% vs 37.9%; RR, 1.21; 95% CI, 0.82-1.81; P = .35; NNT, 12.4) at week 12 or at week 20 (69.3% vs 54.8%; RR, 1.26; 95% CI, 0.95-1.68; P = .11; NNT, 6.9). There was also no significant evidence for differences between CIT and PLA at 4 or 8 weeks. Results of sensitivity analyses did not differ from the main analyses for any of the comparisons, and results of adjusting only randomization stratification variables without race/ethnicity were nearly identical. There was no significant evidence of treatment effect heterogeneity across sites.
We hypothesized that participants with co-occurring MDD would show a greater difference between CIT and PLA than those without MDD. However, there was no significant evidence of an interaction between medication and MDD, with or without CGT (eAppendix 2 in Supplement 2). Replacing MDD by dichotomized severity of depressive symptoms (QIDS-SR16 score ≥16) did not change the results (eAppendix 2 in Supplement 2). However, depressive symptoms decreased significantly more with CGT when CIT was added (CGT with CIT vs CGT with PLA: QIDS-SR16 mean [standard error (SE)] difference, −2.06 [1.00]; 95% CI, −4.02 to −0.11; P = .04). Longitudinal analysis estimated a marginally significant QIDS-SR16 score mean [SE] difference of −1.24 (0.65; P = .06). Figure 2 displays observed mean trajectories of CG (ICG) and depressive (QIDS-SR16) symptoms.
Results of inverse probability weighting–adjusted cross-sectional analyses of mean change in self-report ratings also closely mirrored the main outcome findings (Table 3). Citalopram and PLA showed no significant difference at week 12 for CG symptom severity (ICG-adjusted mean [SE] difference, 0.67 [2.04]; P = .74), grief-related impairment (WSAS-adjusted mean [SE] difference, −0.84 [1.57]; P = .59), or grief-related avoidance (GRAQ-adjusted mean difference, −1.49 [1.56], P = .34); results were similar at week 20. Similarly, CIT with CGT and PLA with CGT were not statistically different on any of these measures at week 20. Citalopram with CGT was associated with significantly greater change than CIT (adjusted mean [SE] differences: ICG, −7.37 [2.08]; P < .001; WSAS, −4.13 [1.46]; P = .005; GRAQ, −5.19 [1.60]; P = .001), and PLA with CGT was associated with significantly greater change than PLA (adjusted mean [SE] differences: ICG, −8.01 [2.04]; P < .001; WSAS, −5.76 [1.63]; P < .001; GRAQ, −5.74 [1.43]; P < .001). Results from longitudinal analyses (mixed effects models) using all available assessments of symptom and impairment measures are consistent with inverse probability weighting analyses (eAppendix 3 in Supplement 2).
At the first treatment visit, rates of suicidal ideation on a clinician-rated suicide assessment were 30.6% for the CIT group, 32.2% for the PLA group, 32.2% for the CIT with CGT group, and 25.9% for the PLA with CGT group (Table 2). Those receiving medication without CGT still reported a wish to die at week 20 (CIT, 17.7%; PLA, 19.0%). Complicated grief treatment with CIT was associated with significantly lower suicidal ideation at week 20 compared with CIT (3.5% vs 17.7%; odds ratio, 0.17; 95% CI, 0.05-0.55; P = .003). Similarly, CGT with PLA at week 20 was significantly lower than PLA (6.7% vs 19.0%; odds ratio, 0.30; 95% CI, 0.11-0.85; P = .02).
Seventy-four percent of those assigned to CGT completed all 16 sessions, and CIT did not significantly improve this completion rate (74.0% vs 73.7%; P = .97). Among participants not assigned to CGT, those receiving CIT were more likely to complete a full course of medication compared with those receiving PLA (62.4% vs 48.5%; P = .05). Medication adherence was greater with CGT with PLA than PLA (68.8% vs 48.5%; P = .004) but not significantly different for CGT with CIT compared with CIT (67.7% vs 62.4%; P = .43). Response rates for treatment completers were slightly higher for each treatment condition; however, results were not significantly different for any of our comparisons.
We observed no serious adverse medication effects (eg, psychiatric or medical hospitalization, suicide attempts, or death [a participant in San Diego died by suicide during the study; review by the study team and institutional review board determined that this death was not related to the research]). Medication dose was adjusted to accommodate adverse effects as needed. Complicated grief treatment therapists monitored participant response to emotionally activating procedures, such as revisiting the death and confrontation with reminders of the deceased, and no serious untoward responses were documented.
Data were obtained for 247 of 395 (62.5%) of all randomized and 247 of 289 (85.5%) of study completers. Rates of maintaining response at 6-month follow-up assessment were 96.4% for CGT with PLA, 93.1% for CGT with CIT, 96.4% for CIT without CGT, and 83.3% for PLA without CGT.
Complicated grief is an underrecognized public health problem estimated to affect tens of millions of people worldwide.1 Symptoms can be reliably assessed and are associated with a chronic course, high levels of suicidality,26-28 and functional impairment comparable to many DSM-5 disorders.18 The severity and chronicity of distress and impairment underscore why intervening clinically with evidence-informed treatment is important. We conducted a randomized clinical trial to determine whether and how antidepressant medication should be used with and without psychotherapy to optimize treatment of CG.
Our results suggest the efficacy of CGT. To our knowledge, this is the third randomized clinical trial of CGT with positive findings and the first to compare it with PLA. Studies of similar psychotherapies have been published that further support the efficacy of this approach.12,29 It is now clear in the first data from a multicenter trial that CGT or a similar psychotherapy is the treatment of choice for CG,5,6,12,29-34 and it is important that clinicians know how to provide this treatment. Our results further indicate that adding antidepressant medication to CGT may not improve CG outcomes; however, medication is likely to improve results for co-occurring depressive symptoms.
Our conclusions regarding the use of antidepressant medication without CGT are less definitive. We did not find evidence for the efficacy of CIT monotherapy in this study at our planned 12-week end point or at any assessment before or after this (ie, 4, 8, 16, or 20 weeks). However, several issues reduce our confidence in considering this a definitive result. One consideration is that US Food and Drug Administration guidelines for CIT implemented more than a year after we initiated the study required us to decrease maximal daily dose from 60 mg to 40 mg. Although the 40-mg dose is consistent with prior studies documenting efficacy for depression,35 it is possible that the response to CIT would have been greater if the higher dose were used. Another issue is that our recruitment rate was slightly lower than expected (90% of our target), and the assessment drop-out rate was over double what we expected. Although we included a statistical correction for assessment drop out, it is impossible to adjust fully for this problem. Citalopram outperformed PLA numerically on almost all analyses, with this difference most pronounced in those who had comorbid major depression at baseline. Citalopram was associated with significantly better adherence to treatment. Given these observations, we conclude that we have not disproved our initial belief that antidepressant medication can be helpful to people with CG (in the absence of appropriately targeted psychotherapy).
Other limitations include that our study sample was primarily white, female, and well-educated; results may not be generalizable to a more diverse sample. Pharmacotherapist use of CGT-informed clinical management and/or unique benefits of research participation may have inflated response rates; however, because study participants in all arms received these, efficacy results were not differentially impacted.
The robust PLA response rate in this study raises the possibility that pharmacotherapist behavior had a therapeutic effect. If so, physicians and other direct care professionals could improve the care of patients with CG if they learn to recognize CG, familiarize themselves with assessment tools such as the ICG8 and/or guided clinical interview for CG,3 prepare to explain and monitor CG symptoms as different from depression,36,37 and provide empathic support and gentle encouragement for re-engaging in daily activities. Behavioral medicine practitioners should learn to administer CGT.3 Materials are available from http://www.complicatedgrief.columbia.edu/ to guide practitioners in achieving these goals.
In summary, CG is a serious, prevalent, and frequently chronic and debilitating condition that needs to be recognized and treated. Complicated grief treatment is the first-line treatment. Our results support the use of antidepressants in conjunction with CGT for relief of co-occurring depressive symptoms. When CGT is unavailable, CGT-informed supportive clinical management with or without antidepressants may be a helpful approach.
Corresponding Author: M. Katherine Shear, MD, Columbia School of Social Work, Columbia University College of Physicians and Surgeons, 1255 Amsterdam Ave, New York, NY 10027 (firstname.lastname@example.org).
Submitted for Publication: January 27, 2016; final revision received March 9, 2016; accepted March 16, 2016.
Published Online: June 8, 2016. doi:10.1001/jamapsychiatry.2016.0892.
Author Contributions: Drs Shear and Wang had full access to all of the data in the study and take full responsibility for the integrity of the data and the accuracy of the data analysis. Drs Shear, Reynolds, Simon, and Zisook are co-first authors of this paper.
Study concept and design: Shear, Reynolds, Simon, Zisook, Wang, Duan, Skritskaya.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Wang, Mauro, Duan.
Obtained funding: Shear, Reynolds, Simon, Zisook, Lebowitz.
Administrative, technical, or material support: Shear, Reynolds, Simon, Zisook, Skritskaya.
Study supervision: Shear, Reynolds, Simon, Wang, Mauro, Duan, Lebowitz, Skritskaya.
Conflict of Interest Disclosures: Dr Shear reported grant funding from the US Department of Defense, Congressionally Directed Medical Research Programs and a contract from Guilford Press to write a book on grief. Dr Simon reported grant funding from the American Cancer Society, Department of Defense and Highland Street Foundation; support for speaking, participating in continuing medical education, and consulting for the Massachusetts General Hospital Psychiatry Academy and Pfizer Pharmaceuticals; and spousal equity in Dandreon, G Zero, and Gatekeeper. Dr Reynolds reported receiving pharmaceutical support for National Institutes of Health–sponsored research studies from Bristol-Myers Squibb, Forest, Pfizer, and Lilly; receiving grants from the National Institute of Mental Health, National Institute on Aging, National Center for Minority Health Disparities, National Heart, Lung, and Blood Institute, Center for Medicare and Medicaid Services, Patient Centered Outcomes Research Institute, the Commonwealth of Pennsylvania, the John A. Hartford Foundation, National Palliative Care Research Center, Clinical and Translational Science Institute, and the American Foundation for Suicide Prevention; and serving on the American Association for Geriatric Psychiatry editorial review board. He has received an honorarium as a speaker from MedScape/WebMD. He is the coinventor (licensed intellectual property) of psychometric analysis of the Pittsburgh Sleep Quality Index PRO10050447, supported by the National Institutes of Health through grants P60 MD000207, P30 MH090333, UL1RR024153, and UL1TR000005 and the University of Pittsburgh Medical Center endowment in geriatric psychiatry.
Funding/Support: This work was supported by grants R01MH60783, R01MH085297, R01MH085288, R01MH085308, and P30 MH90333 from the National Institutes of Health and by grant LSRG-S-172-12 from the American Foundation for Suicide Prevention.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
Additional Contributions: We also acknowledge the contributions of the Data and Safety Monitoring Board and study site investigative teams including the following individuals, without whose assistance this project would not have been possible: Data and Safety Monitoring Board: Laura Roberts, MD, Palo Alto, California (chair); Peter Roy-Byrne, MD, Seattle, Washington; and Philip Lavori, PhD, Palo Alto, California. Study Investigative Teams: Columbia University, New York, New York: John Bean, LCSW; Devangere Devanand, MD; Angela Ghesquiere, PhD; Kim Glickman, PhD; Colleen Gribbin, MA; Tino Huynh, MD; Xin Qiu, MS; Shanthi Mogali, MD; Gregory Pelton, MD; Steven Roose, MD; Suzanne Jacquez-Sanchez, LCSW; and Nancy Turret, LCSW. University of Pittsburgh, Pittsburgh, Pennsylvania: Claudia DiNardo, MSW; Bonnie Gorscak, PhD; Jordan F. Karp, MD; Michael Lockovich, LCSW; Mary McShea, MS; Mark D. Miller, MD; Valerie Richards, PhD; Jacqueline Stack, MSN; Elizabeth Weber, MSN, CRNP; Kelley Wood, BS; and Rebecca Zoretich, MS. Massachusetts General Hospital, Boston, Massachusetts: Amanda W. Baker, PhD; Eric Bui, MD, PhD; Meredith E. Charney, PhD; Cristina Cusin, MD; Elizabeth M. Goetter, PhD; Arielle Horenstein, BA; Nicole LeBlanc, BA; Luana Marques, PhD; Cynthia W. Moore, PhD; Donald J. Robinaugh, PhD; Mireya Nadal-Vicens, MD, PhD; and John J. Worthington, MD. University of California, San Diego, California: Julie Avanzino, BA; Sanaz Farhadian, PharmD; Liane Fry, LMFT; Danielle Glorioso, LCSW; Alana Iglewicz, MD; Nicole Lanouette, MD; Jeanne Maglione, MD; Janet McClure, PhD, RN; Kathryn Resovsky, RN; Kathryn Baker Seay, MS; Ipsit Vahia, MD; Julie Wetherell, PhD; and Ilanit Tal Young, PhD. All contributors received compensation.
Create a personal account or sign in to: